FDA's Opioid Policy Reboot: New Risk-Benefit Model, Real-World Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Science Board also suggests ways to improve REMS-mandated prescriber education.
You may also be interested in...
Purdue's Butrans: US FDA Panel To Consider Pediatric Labeling, But Not A New Indication
Purdue says it conducted a trial required under the Pediatric Research Equity Act but is not seeking a formal indication and will not promote the opioid for pediatric populations. Two advisory committees will discuss the trial results and whether they support additional labeling for the buprenorphine transdermal product Sept. 14.
The Politics Of Opana: US FDA’s Opioid Problems Won’t Go Away
A two-day safety review of Endo’s reformulated Opana ER provided strong support for FDA’s view that products using abuse-deterrent technology cannot simply be assumed to be 'safer' than conventional formulations. However, there are also no easy answers for when and how FDA will be able to move out of the hot seat on opioid abuse.
Pfizer’s Troxyca And The Limits Of Advisory Committee Review For Opioids
FDA approved Pfizer’s oxycodone/naltrexone extended release opioid with abuse deterrent claims similar to Embeda. That isn’t the label FDA’s advisory committee supported.